Effect of peptides derived from food proteins on blood pressure: a meta-analysis of randomized controlled trials

Are Hugo Pripp
Research Services Department, Rikshospitalet, Oslo, Norway

Abstract

Background: In clinical trials, peptides derived from food proteins have shown an effect on blood pressure. This biological mechanism is mainly due to inhibition of angiotensin-I-converting enzyme (ACE), thereby regulating blood pressure through the renin-angiotensin system. A meta-analysis of these trials is needed to better quantify their effect, sources of variation, and possible publication bias.

Objective: To perform a meta-analysis of placebo-controlled clinical trials on peptides derived from food proteins and their effect on blood pressure.

Design: Trials identified using a defined search strategy in PubMed were included in the meta-analysis, and their pooled effect was estimated with a random effects model.

Results: Pooled effect of peptides was $-5.13$ mmHg (95% CI: $-7.12$, $-3.14$) for systolic blood pressure, and $-2.42$ mmHg (95% CI: $-3.82$, $-1.03$) for diastolic blood pressure. There were indications of publication bias for diastolic blood pressure data.

Conclusions: Peptides derived from food proteins may lead to significantly reduced blood pressure and could therefore be a supplement or alternative to pharmaceutical treatment for mild hypertension. Their effect seems more pronounced, or at least comparable, to that of other food components studied by randomized controlled trials. A high proportion of the reported trials was carried out using the well-known ACE inhibiting tripeptides – Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP).

Keywords: angiotensin-I-converting enzyme (ACE); clinical trials; hypertension

Received: March 19, 2007; Revised: September 28 2007; Accepted: October 20, 2007

High blood pressure, which is estimated to affect one-third of the Western population, is an important risk factor for coronary heart disease, stroke and renal disease (1). Lifestyle modifications, including weight loss, quitting smoking, reducing sodium and alcohol intake, increasing physical activity and changing diet, are recommended for both treatment and prevention (2). Besides the recommendation of general lifestyle changes, efforts have been made to produce functional foods that contain components – nutraceuticals – which have a blood pressure reducing effect, and could be a supplement or alternative to the pharmaceutical treatment of hypertension. Bioactive peptides with angiotensin-I-converting enzyme (ACE) inhibitory and antihypertensive effects have been the focus of special attention. They have been isolated from several food sources, biochemically characterized, and currently, some commercial food products with clinically proven effects are used (3). Specifically, milk and dairy products have been shown to have good effects (4). Results from extensive randomized, blinded and placebo-controlled clinical trials are needed to scientifically support claimed effects. Therefore, it is important to systematically summarize the findings from such clinical trials on antihypertensive bioactive peptides derived from foods.

Meta-analysis has been defined as ‘the statistical analysis of a large collection of analysis results from individual studies for the purpose of integrating the finding’ (5). It goes beyond an expert literature review where the results from various studies are discussed and compared, since it synthesizes the results of the individual studies into a new, pooled, result using statistical methodology (6). This enhances the precision of the estimates of treatment effects, thereby leading to improvement in clinical strategies (7). Even though the number of expert literature reviews on antihypertensive peptides from food sources is extensive, to my knowledge a meta-analysis of placebo-controlled clinical trials has not been performed. A meta-analysis would contribute to an improved understanding of the effectiveness of pep-
tides in hypertension and whether these could be a feasible supplement to pharmaceutical treatment. The possible presence of publication bias in these trials was also investigated.

**Methods**

**Selection of studies**

As part of finding a defined search string in PubMed for relevant clinical trials, literature reviews and selected clinical trials on bioactive peptides derived from food proteins were studied. Several searches of databases and the Internet were also carried out, providing an overview of the subject. It was also discovered that some reports have only been published in Japanese. To avoid problems and limitations with the translation of these reports, it was decided to perform this meta-analysis solely on trials published in English. The strategy was to develop a defined search string that would find all relevant clinical trials registered in PubMed. The literature reference list of the selected trials would then be carefully examined to identify any supplementary trials not registered in PubMed. The defined search string in PubMed with generated translations of expressions is shown in Box 1. By 1 July 2007 it gave 227 hits of which 13 trials were found relevant for further examination by meta-analysis.

**Data abstraction**

Number, age and sex-ratio of participants, duration of intervention, baseline systolic (SBP) and diastolic blood pressure (DBP), change at end of intervention and daily amount of active component or placebo product were obtained from each trail (Tables 1 [10–22] and 2). In a trial by Mizuno et al. (9), participants were given different amounts of active product. Only data from the group of participants given the highest amount were abstracted for use in the meta-analysis.

**Statistical analysis**

The effect of intervention or placebo was not estimated identically in the trials. This effect was estimated either with a within or between subject comparison of the participants’ blood pressure at the start and end of trial (Table 3). Statistically, let $X_{ij}$ be the blood pressure for the intervention group, where $i = 1$ or 2 which is at start or end of trial, respectively, and $j = 1, 2, \ldots, n$ is the participants with active intervention. Further, let $Y_{ij}$ be the blood pressure for the placebo control group, where $i = 1$ or 2 which is at start or end of trial, respectively, and $j = 1, 2, \ldots, m$ is the participants with placebo control.

For within subject comparison, the mean effect of intervention is defined as

$$I = \frac{1}{n} \sum_{j=1}^{n} I_{ij} = \frac{1}{n} \sum_{j=1}^{n} (X_{2j} - X_{1j})$$  \hspace{1cm} (1)

and for placebo

$$P = \frac{1}{m} \sum_{j=1}^{m} P_{ij} = \frac{1}{m} \sum_{j=1}^{m} (Y_{2j} - Y_{1j}).$$  \hspace{1cm} (2)
For between subject comparison, the mean effect of intervention is defined as

\[ \bar{I} = \frac{1}{n} \sum_{j=1}^{n} I_j = \frac{1}{n} \sum_{j=1}^{n} X_{ij} \]  

(3)

and for placebo

\[ \bar{P} = \frac{1}{m} \sum_{j=1}^{m} P_j = \frac{1}{m} \sum_{j=1}^{m} Y_{ij}. \]  

(4)

Estimates of the mean effect of intervention and placebo with standard deviations (SD\(_I\) and SD\(_P\)) were obtained from the studies. For meta-analysis, the trial effect for both within subject and between subject comparisons could then be estimated by

\[ \bar{I} - \bar{P} \]  

with standard error of trial effect given by

\[ \sqrt{\frac{1}{n} + \frac{1}{m}} \sqrt{\frac{(n-1)SD_I^2 + (m-1)SD_P^2}{(n+m-2)}}. \]  

(6)

Both fixed and random effects models were examined to calculate the mean pooled effect size with confidence intervals. The homogeneity among studies was tested using Cochran’s Q-test (23). In this paper, results presented are based on a random effects model. To calculate a pooled effect size, each study was assigned a weight. The random effects weighted model by DerSimonian and Laird (24) based on the inverse variance was used. Publication bias was visually examined after construction of a funnel plot, where standard error is plotted against net changes in blood pressure. In addition, Egger regression and its corresponding test for publication bias were performed (25). The effect and quality of individual trials were examined by making cumulative and exclusion sensitivity forest plots (7). Meta-regression with trial effects as dependent variable and combined amounts of tripeptides Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP) in trials as independent variable weighted by the inverse variance from the random effect model was performed.

Statistical calculations for meta-analysis and generation of plots were performed using the MIX software, version 1.54 (26), and weighted least square regression for meta-regression was preformed using SPSS 15.0.1 for Windows (Chicago, IL, USA).

**Results**

**Study characteristics**

Characteristics of the included trials for meta-analysis are given in Tables 1 and 2. A total of 826 participants completed the trials. In the study by Kawase et al. (12) DBP was not measured. All trials have been published in international peer-reviewed journals. Mean duration of intervention was 7.4 weeks with a minimum intervention of 4 weeks. More than half of the trials used intervention with the bioactive peptides IPP and VPP. In most of the trials, participants were aged more than 50 years on average, with a higher proportion of males than females.

**Quantitative data synthesis**

Cochran’s Q-test for homogeneity among studies gave \( Q = 30.52 \) for SBP data with a p-value of 0.02, and \( Q = 29.10 \) for DBP data with a p-value of 0.08. This indicated heterogeneity among the studies, and a random effects model was used for meta-analysis. Exclusion sensitivity plots showed that excluding single studies did not affect pooled results from meta-analysis by more than approximately 0.5 mmHg (results not shown). The weighted
pooled effect size for trials with bioactive peptides derived from food proteins was \(-5.13\) mmHg (95% CI: \(-7.12, -3.14\)) for SBP (Fig. 2), and \(-2.42\) mmHg (95% CI: \(-3.82, -1.03\)) for DBP (Fig. 3). Meta-regression relating combined amounts per day of IPP and VPP (mg) with effect on blood pressure was performed, but no statistically significant effect at the 5% level was found. Difference between studies with Western or Asian population was also examined. Asian studies had a somewhat larger reduction in blood pressure, but there was no statistically significant difference at the 5% level. No statistically significant effect was found for the proportion of males in the studies.

**Publication bias**

Funnel plots of SBP and DBP (Fig. 4) indicated signs of publication bias for DBP. This was partly confirmed by the Egger regression test for publication bias, which gave p-values of 0.31 and 0.08 for SBP and DBP results, respectively. There was no indication of repeated publications of the same trials.

**Discussion**

Results from the meta-analysis of the clinical trails showed that peptides derived from food proteins can significantly reduce SBP and DBP, with pooled mean effects of \(-5.13\) mmHg (95% CI: \(-7.12, -3.14\)) and \(-2.42\) mmHg (95% CI: \(-3.82, -1.03\)), respectively. There were some signs of heterogeneity and publication bias among the trials, but exclusion sensitivity analysis did not indicate that one specific trial had a major impact on the pooled effect estimate. A high proportion of the reported trials were carried out using the ACE-inhibiting tripeptides VPP and IPP.

On studying the research literature on bioactive peptides derived from food proteins, it is striking that the number of research papers and literature reviews is extensive compared to the number of controlled clinical trials. Nutraceuticals or functional foods are not subject to the same strict legislation and documentation requirement using randomized controlled clinical trials, as is the case for pharmaceuticals. Much work is based on in vitro assays or to a certain extent animal (rat) experiments. Extensive searches in other databases, such as the Cochrane Library or the Internet, did not yield additional English-language placebo-controlled clinical trials published in peer-reviewed journals. However, there are some other trials written in Japanese. Based on official English translations of abstracts, many of the trials used IPP and VPP peptides as active components and their effect on blood pressure was comparable to those reported in this meta-analysis.

Cochrane’s Q-test indicated heterogeneity among the studies. The trials were performed by different groups with different active components. The number of trials was also too limited to perform meta-regression to test for many

---

**Table 1.** Baseline characteristics of clinical trials included for meta-analysis with mean and standard deviation values

<table>
<thead>
<tr>
<th>Source</th>
<th>n</th>
<th>SBP (mmHg)</th>
<th>DBP (mmHg)</th>
<th>Age</th>
<th>Male (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hata et al. (10)</td>
<td>17</td>
<td>159 (46)</td>
<td>89 (39)</td>
<td>77 (31)</td>
<td>23</td>
</tr>
<tr>
<td>Kawasaki et al. (11)</td>
<td>17</td>
<td>146 (10)</td>
<td>91 (7)</td>
<td>46 (13)</td>
<td>94</td>
</tr>
<tr>
<td>Kawase et al. (12)</td>
<td>10</td>
<td>124 (10)</td>
<td>NA</td>
<td>NA</td>
<td>100</td>
</tr>
<tr>
<td>Fujita et al. (13)</td>
<td>30</td>
<td>150 (9)</td>
<td>94 (10)</td>
<td>62 (8)</td>
<td>60</td>
</tr>
<tr>
<td>Seppo et al. (14)</td>
<td>10</td>
<td>148 (13)</td>
<td>94 (6)</td>
<td>49 (6)</td>
<td>30</td>
</tr>
<tr>
<td>Seppo et al. (15)</td>
<td>22</td>
<td>155 (13)</td>
<td>97 (6)</td>
<td>51 (7)</td>
<td>46</td>
</tr>
<tr>
<td>Mizushima et al. (16)</td>
<td>23</td>
<td>148 (10)</td>
<td>95 (10)</td>
<td>44 (10)</td>
<td>100</td>
</tr>
<tr>
<td>Tounilehto et al. (17)</td>
<td>30</td>
<td>153 (10)</td>
<td>98 (7)</td>
<td>51 (10)</td>
<td>NA</td>
</tr>
<tr>
<td>Aihara et al.* (8)</td>
<td>20</td>
<td>137 (6)</td>
<td>85 (11)</td>
<td>53 (11)</td>
<td>65</td>
</tr>
<tr>
<td>Aihara et al.** (8)</td>
<td>20</td>
<td>147 (9)</td>
<td>92 (9)</td>
<td>52 (12)</td>
<td>80</td>
</tr>
<tr>
<td>Jauhiainen et al. (18)</td>
<td>53</td>
<td>149 (7)</td>
<td>94 (6)</td>
<td>51 (12)</td>
<td>66.0</td>
</tr>
<tr>
<td>Mizuno et al.* (9)</td>
<td>12</td>
<td>134 (3)</td>
<td>82 (5)</td>
<td>NA</td>
<td>12</td>
</tr>
<tr>
<td>Mizuno et al.** (9)</td>
<td>21</td>
<td>149 (5)</td>
<td>88.6 (5)</td>
<td>NA</td>
<td>20</td>
</tr>
<tr>
<td>Sano et al. (19)</td>
<td>72</td>
<td>138 (7)</td>
<td>85 (5)</td>
<td>51 (10)</td>
<td>40.3</td>
</tr>
<tr>
<td>Cadée et al. (20)</td>
<td>24</td>
<td>138 (12)</td>
<td>87 (10)</td>
<td>56 (11)</td>
<td>25</td>
</tr>
<tr>
<td>Lee et al. (21)</td>
<td>27</td>
<td>144 (9)</td>
<td>91 (6)</td>
<td>55 (10)</td>
<td>52</td>
</tr>
<tr>
<td>Pins et al. (22)</td>
<td>15</td>
<td>137 (11)</td>
<td>84 (7)</td>
<td>46 (13)</td>
<td>47</td>
</tr>
</tbody>
</table>

*Data from participants with high-normal blood pressure.
**Data from participants with mild hypertension.
sources of heterogeneity, and the effect of daily intake of VPP and IPP was not significant. Meta-regression can be carried out to relate the results of trials to the average participant’s characteristics, such as blood pressure or age, but an interpretation of such results is difficult and should be carried out with care. This is because the relationship with participant averages across trials may not be the same as the relationship for participants within trials (27). Therefore, it was not performed in this meta-regression. Egger regression, funnel plots (Fig. 4) and cumulative Forrest plots (results not shown) did indicate signs of publication bias, especially for DBP results. One might speculate that some studies with low accuracy, e.g. with few included participants and with little or negative effects, have not been published in international peer-reviewed journals. Typically, this could have been minor research or student projects. Therefore, the random effects model was used because of the possible presence of heterogeneity and its appropriateness to test whether a treatment will have an effect ‘on average’ (28).

Results from this meta-analysis gave a significant reduction on both SDP and DBP at \( p < 0.01 \). However,
Table 3. Calculating the effect of trials based on within or between subject comparison of intervention and placebo control treatment

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention SBP</th>
<th>Intervention DBP</th>
<th>Placebo control SBP</th>
<th>Placebo control DBP</th>
<th>Effect of trial SBP</th>
<th>Effect of trial DBP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Effect (SE)</td>
<td>Effect (SE)</td>
</tr>
</tbody>
</table>
| Within subject comparison of blood pressure
| Hata et al. (10)       | -14.1 (12.8)     | -6.9 (10.3)      | -4.4 (13.0)         | -2.2 (6.9)          | -9.7 (4.7)          | -4.7 (3.3)          |
| Seppo et al. (14)      | -14.9 (9.4)      | -8.8 (6.8)       | -4.1 (11.4)         | -2.0 (5.2)          | -10.8 (5.0)         | -6.9 (3.1)          |
| Seppo et al. (15)      | -15.4 (8.3)      | -9.3 (4.8)       | -9.4 (13.2)         | -5.5 (7.4)          | -6.0 (3.6)          | -3.8 (2.1)          |
| Mizushima et al. (16)  | -5.2 (11.3)      | -2.0 (8.0)       | -3.7 (10.6)         | -0.3 (8.3)          | -1.5 (3.2)          | -1.7 (2.4)          |
| Toumilehto et al. (17) | -15.8 (13.2)     | -10.3 (6.5)      | -13.5 (11.9)        | -9.8 (7.5)          | -2.3 (3.3)          | -0.5 (1.8)          |
| Aihara et al.* (8)     | -5.0 (8.9)       | -6.0 (6.7)       | -2.0 (8.9)          | -1.0 (8.9)          | -3.0 (2.8)          | -5.0 (2.5)          |
| Aihara et al.** (8)    | -10.0 (15.7)     | -7.5 (15.7)      | 0.5 (11.2)          | -0.5 (8.9)          | -10.5 (4.3)         | -7.0 (4.0)          |
| Jauhianinen et al. (18)| -5.1 (9.4)       | -1.1 (5.6)       | -3.1 (11.5)         | -2.1 (6.1)          | -2.0 (2.0)          | 1.0 (1.1)           |
| Cadée et al. (20)      | -10.7 (7.8)      | -6.9 (5.9)       | -3.6 (11.8)         | -2.7 (7.8)          | -7.1 (2.9)          | -4.2 (2.0)          |

Between subject comparison of blood pressure

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention SBP</th>
<th>Intervention DBP</th>
<th>Placebo control SBP</th>
<th>Placebo control DBP</th>
<th>Effect of trial SBP</th>
<th>Effect of trial DBP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Effect (SE)</td>
<td>Effect (SE)</td>
</tr>
<tr>
<td>Kawasaki et al. (11)</td>
<td>137.1 (12.0)</td>
<td>85.3 (8.6)</td>
<td>142.5 (11.5)</td>
<td>91.0 (8.7)</td>
<td>-5.4 (4.4)</td>
<td>-5.7 (3.2)</td>
</tr>
<tr>
<td>Kawase et al. (12)</td>
<td>118.0 (9.5)</td>
<td>- -</td>
<td>125.0 (14.2)</td>
<td>- -</td>
<td>-7.0 (5.4)</td>
<td>- -</td>
</tr>
<tr>
<td>Fujita et al. (13)</td>
<td>137.5 (11.5)</td>
<td>86.5 (8.2)</td>
<td>148.5 (9.9)</td>
<td>92.0 (8.4)</td>
<td>-11.0 (2.7)</td>
<td>-5.5 (2.1)</td>
</tr>
<tr>
<td>Mizuno et al.* (9)</td>
<td>131.1 (5.8)</td>
<td>79.8 (6.0)</td>
<td>133.1 (5.5)</td>
<td>79.2 (4.3)</td>
<td>-2.0 (2.3)</td>
<td>0.6 (2.1)</td>
</tr>
<tr>
<td>Mizuno et al.** (9)</td>
<td>135.0 (10.9)</td>
<td>83.9 (8.8)</td>
<td>147.2 (10.8)</td>
<td>87.3 (7.3)</td>
<td>-12.2 (3.4)</td>
<td>-3.4 (2.5)</td>
</tr>
<tr>
<td>Sano et al. (19)</td>
<td>132.3 (7.3)</td>
<td>81.2 (4.8)</td>
<td>136.4 (8.0)</td>
<td>83.7 (5.6)</td>
<td>-4.1 (1.3)</td>
<td>-2.5 (0.9)</td>
</tr>
<tr>
<td>Lee et al. (21)</td>
<td>147.3 (13.5)</td>
<td>90.4 (6.5)</td>
<td>137.0 (14.4)</td>
<td>87.7 (6.6)</td>
<td>6.7 (3.8)</td>
<td>2.7 (1.8)</td>
</tr>
<tr>
<td>Pins et al. (22)</td>
<td>126.0 (6.2)</td>
<td>77.0 (5.4)</td>
<td>133.0 (7.4)</td>
<td>80.0 (5.8)</td>
<td>-7.0 (2.5)</td>
<td>-3.0 (2.1)</td>
</tr>
</tbody>
</table>

*Data from participants with high-normal blood pressure.
**Data from participants with mild hypertension.

Fig. 2. Standard forest plot from meta-analysis on systolic blood pressure. Cochran’s Q-test for homogeneity was \( Q = 30.52, p\)-value = 0.02.

Fig. 3. Standard forest plot from meta-analysis on diastolic blood pressure. Cochran’s Q-test for homogeneity was \( Q = 29.10, p\)-value = 0.08.
their blood pressure reducing effect seems limited in the range of 2–7 mmHg.

Many of the clinical trials were also carried out using the well-known ACE inhibiting tripeptides, IPP and VPP. Additional clinical trials on non-specific food protein hydrolysates could provide a better understanding if the effect on blood pressure is limited to some specific peptide structures or is a general property of many peptides derived from food proteins. Lee et al. (21) was the only study in which active treatment did not, on average, reduce blood pressure. They used a hydrolysate, and the content of specific bioavailable ACE-inhibiting peptides, such as Valine-Tyrosine (VY), IPP or VPP, was not identified. That could indicate that the presence of some specific bioactive peptides is important for clinical effect, but further investigations are needed to draw such conclusions. Stratified meta-analysis of trials with or without tripeptides IPP and VPP gave −4.59 mmHg (95% CI: −6.61, −2.57) or −5.42 mmHg (95% CI: −10.10, −0.76) for SBP and −2.20 mmHg (95% CI: −3.73, −0.67) or −2.87 mmHg (95% CI: −6.17, 0.44) for DBP, respectively.

Another interesting result from this stratified meta-analysis was that the Cochrane Q-test was significant for trials without VPP and IPP (p = 0.02 for both SBP and DBP), but not for trials with IPP and VPP (p = 0.16 and 0.08 for SBP and DBP, respectively). Bioinformatic modelling has, for instance, indicated that the pre-hydrolysis of proteins in foods may influence bioavailability and the ACE-inhibitory effect after digestion (29).

The effect of peptides may also be related to the association found between protein intake and reduced blood pressure from meta-analysis of epidemiological data on dietary protein intake (30). Research on bioactive peptides is extensive within the dairy field, and most of the clinical trials used milk-based products (Table 2). However, lack of controlled clinical trials examining the effect of different proteins makes it difficult to say if the original protein source for bioactive peptides is important for their effect on blood pressure. This area needs further studies.

Antihypertensive peptides have limitations as pharmaceuticals since they are susceptible to degradation by proteolytic enzymes in the stomach and intestines during digestion and because of their limited bioavailability (31). However, compared to other blood pressure reducing components derived from food sources, bioactive peptides seem to be competitive. For instance, meta-analysis of fibre supplementation gave a non-significant reduction of SBP by 1.2 mmHg and a significant 1.5 mmHg reduction of DBP (32, 33). Recent meta-analyses of potassium and magnesium supplementation found no significant effect on blood pressure (34, 35), but is somewhat contradicted by other previous meta-analyses (36–38). Calcium supplementation has shown to significantly effect SBP by −1.86 mmHg (95% CI: −2.91, −0.81) and DBP by −0.99 mmHg (95% CI: −1.61, −0.37) in a meta-analysis by van Mierlo et al. (39), but this significant effect has been contradicted by Dickinson et al. (40), who claimed it was due to poor quality, heterogeneity and biases among trials. For individuals with elevated blood pressure, a Cochrane review on salt reduction found a significant reduction in SBP of −5.06 mmHg (95% CI: −5.81, −4.31) and DBP of −2.70 mmHg (95% CI: −3.16, −2.24). Blood pressure reduction in individuals with normal blood pressure was somewhat less (41). In meta-analysis, fish oil supplementation showed an effect on SBP of −2.1 mmHg (95% CI: −3.2, −1.0) and DBP of −1.6 mmHg (95% CI: −2.2, −1.0) (42). Meta-analysis of clinical trials with garlic preparations showed a significant reduction in blood pressure, but the investigators concluded that there was insufficient evidence to recommend it as a routine clinical therapy for the treatment of hypertensive subjects (43).

Even though this meta-analysis only showed a limited effect of peptides derived from food proteins on blood pressure, it could be an alternative or supplement to
pharmacological treatment in combination with other lifestyle changes. In more severe hypertension, when a reduction of >10 mmHg is needed (44), the limited effect of these bioactive peptides might not provide adequate treatment. Clinical trials comparing bioactive peptides with pharmaceuticals are needed to gain better insight into how effective bioactive peptides could be as an alternative to medical treatment. The role of food-derived peptides in diminishing the risk of hypertension remains to be established.

Conflict of interest and funding
The author has not received any funding or benefits from industry to conduct this study.

References

Are Hugo Pripp
Research Services Department, Biostatistics Group, Rikshospitalet, Sognsvannsveien 20, 0027 Oslo, Norway.
E-mail: are.hugo.pripp@rikshospitalet.no